The independent lawsuits allege Merck fielded a “monopolistic scheme” that allowed them to maintain strong profits as new chemical exclusivity periods drew to a close.
According to the lawsuits, both Merck and Glenmark Pharmaceuticals colluded to maintain control over Zetia and Vytorin and bring in profits, both by delaying Glenmark’s authorized generic and not releasing a Merck generic.
By the time Glenmark entered the market after planned delays, the insurers overpaid hundreds of millions of dollars for the drugs, the lawsuits allege.
Merck and Glenmark did not reply to Becker’s requests for comment at the time of publication.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
